Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 46 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
C&J Laboratories Belgium from Sint-Niklaas, company number BE0645680597, closed financial year 2025 with a result of € 11,178 after tax. For that financial year C&J Laboratories Belgium recorded a gross margin of € 77,087 and equity of € 37,338. Compared with financial year 2024, the result moved from € 31,261 to € 11,178. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 37,338
▲ 43% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 11,178
▼ 64% vs 2024
Profit after tax over the fiscal year.
€ 9,790
▼ 34% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 17,338.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 58,574
▲ 8% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 3,598
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 58,105
Loans from banks and other lenders, long and short.
€ 25,608
▲ 31% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 16,832
▼ 21% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 58,893 | € 89,739 | € 93,105 | € 77,087 | ▼ 17% |
| Profit after taxes | € 12,072 | € 39,897 | € 31,261 | € 11,178 | ▼ 64% |
| Equity | € -44,997 | € -5,100 | € 26,160 | € 37,338 | ▲ 43% |
| Total debts | € 147,069 | € 119,059 | € 127,975 | € 129,542 | ▲ 1% |
| Cash | € 47,407 | € 26,603 | € 14,780 | € 9,790 | ▼ 34% |
| Retained profit | € -64,997 | € -25,100 | € 6,160 | € 17,338 | ▲ 181% |
| Bank debt | € 58,105 | € 58,105 | € 58,105 | € 58,105 | |
| Balance sheet total | € 102,072 | € 113,959 | € 154,135 | € 166,880 | ▲ 8% |
Key figures of C&J Laboratories Belgium, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to C&J Laboratories Belgium?
What happened at C&J Laboratories Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 11,178 (▼ 64% vs 2024). Source: NBB ↗
- Carl Seys became a director. NBB
- Vitasol became a director. NBB
- New establishment in Sint-Niklaas. KBO
- Start of the company according to the CBE. KBO
In short
From € 12,072 profit in 2022 to € 11,178 profit in 2025.
Paid € 14,479 in corporate taxes since 2022.
Best year ever: 2023, with € 39,897 profit.
A new publication or filing at C&J Laboratories Belgium? We notify you, reason included.
Follow C&J Laboratories BelgiumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind C&J Laboratories Belgium are Carl Seys and Vitasol. The same people are also behind STARIUS CLASSICS and CANARY. Carl Seys is also behind Jacobs, VIVENTA, STARIUS, BERNARD and VitaSol.
Establishments
Establishment units
Physical locations of this company
Driegaaienstraat 192+
9100 Sint-Niklaas
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0645.680.597
- VAT number
- BE 0645.680.597
- Registered office
- Driegaaienstraat 192+, 9100 Sint-Niklaas
- Names & denominations
- C&J Laboratories Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 January 2016
- Peppol
- Active · Active since 20 Apr 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Vervaardiging van overige farmaceutische producten